**Tecovirimat Treatment Considerations (Guidance for Tecovirimat Use):**

For people infected with Monkeypox virus, treatment should be considered for those with:

- **Severe disease,** such as hemorrhagic disease, confluent lesions, sepsis, encephalitis, or other conditions requiring hospitalization

- **High risk of progression to severe disease:**
  - People with immunocompromising conditions (e.g., HIV/AIDS, leukemia, lymphoma, generalized malignancy, solid organ transplantation, therapy with alkylating agents, antimetabolites, radiation, tumor necrosis factor inhibitors, high-dose corticosteroids, being a recipient with hematopoietic stem cell transplant <24 months post-transplant or ≥24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component)
  - Pediatric populations, particularly patients younger than 8 years of age
  - Pregnant or breastfeeding women
  - People with a history or presence of atopic dermatitis, people with other active exfoliative skin conditions
  - People with one or more complication (e.g., secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhea, or dehydration; bronchopneumonia; concurrent disease or other comorbidities)

- **Aberrant infections involving accidental implantation in eyes, mouth, or other anatomic areas where Monkeypox virus infection might constitute a special hazard (e.g., the genitals or anus)**

- **Any other complications not otherwise stated above (e.g., intractable pain) that a healthcare provider determines as warranting treatment**

**To Request Treatment:**

CDC holds a non-research expanded access Investigational New Drug (EA-IND) protocol that allows for the use of Tecovirimat **(package insert)** for treatment of orthopoxvirus infections, including monkeypox. The EA-IND provides an umbrella regulatory coverage so that clinicians and facilities do not need to request and obtain their own INDs. Oral and IV formulations are available.

Tecovirimat is only available through the federal Strategic National Stockpile and must be requested via the Connecticut Department of Public Health (DPH). Please email dph.monkeypox@ct.gov if you are interested in prescribing tecovirimat for your patients.

Once the email is received, you will be contacted by public health personnel to briefly discuss the documentation required by CDC for tecovirimat use under the EA-IND and arrange for pick-up of the medication. Consent forms and the FDA Form 1572 must be submitted to CDC (regaffairs@cdc.gov or fax 404-902-5921) and Connecticut PDH (dph.monkeypox@ct.gov). The consent forms must be submitted prior to tecovirimat treatment initiation. Providers are responsible for arranging the pick-up of the medication from DPH at 410 Capitol Avenue, Hartford, Connecticut.
DPH will follow-up with providers to gather information about start and stop dates, patient progress, complications, adverse effects, and any other information that may be deemed pertinent.